Cholesterol lowering drugs may create small increase in risk of developing diabetes, researchers reveal today.
The new study reveals the mechanism by which statin drugs raise the risk of type 2 diabetes – showing that the risk comes from the drugs themselves and that they can stimulate weight gain.
Experts said the risk could be counteracted by taking extra steps to keep a healthy weight.
Dr David Preiss, of Glasgow University, UK, and colleagues carried out a large-scale analysis of genetic studies and clinical trials.
Looking at information from nearly 130,000 participants in statin trials, the team found an increase of about 12% in risk of developing type 2 diabetes over a four-year period. Statins were also linked to a gain of 240g in weight, or about half a pound.
The analysis is published in The Lancet today (24 September). Dr Preiss said: "Weight gain is a risk factor for diabetes which might help explain the small increased risk of diabetes observed in people taking statins."
Co-author Dr Daniel Swerdlow added: "Incorporating information from up to 220,000 individuals, we found that certain genetic variants were also associated with a higher weight and marginally higher type 2 diabetes risk.
"The effects were very much smaller than from statin treatment, but the genetic findings indicate that the weight gain and diabetes risk observed in the analysis from trials are related to the known mechanism of action of statins rather than some other unintended effect."
The team point out that there is also no suggestion from this study that an individual’s genetic make-up will meaningfully affect their clinical response to statin treatment. "Statin drugs should continue to be prescribed without the need for any form of genetic testing," they write.
Current guidelines from the UK National Institute for Health and Care Excellence (NICE) recommend offering statins to people with a 10% or higher risk of developing cardiovascular disease in the next ten years.
The British Heart Foundation said the findings showed that taking statins was not a substitute for keeping a healthy weight.
Associate medical director Professor Jeremy Pearson said: “This study should reassure people that the benefits of taking statins far outweigh the small effect on diabetes risk. But the results also reinforce that, alongside prescribed medication, taking steps to maintain a healthy weight is essential to stay heart healthy.”
Swerdlow, D. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet 23 September 2014 doi:10.1016/S0140-6736(14)61183-1 [abstract]

Leave a Reply